Method for chemoradiation therapy of brain malignant glial tumor
FIELD: medicine, oncology.
SUBSTANCE: method involves carrying out lumbal puncture to a patient in post-operative period, subarachnoid space is catheterized, and 5 ml of liquor is removed followed by incubation of liquor with nimustine taken in the dose 5 mg in vitro at temperature 38°C for 30 min, and liquor is administrated into subarachnoid space through catheter. Procedure is carried out 2 times with interval for 7 days. Since the second day after onset of this procedure distant gamma-therapy on bed of removed tumor is carried out up to the total focus dose 60 Gr. Method provides stable remission, decreasing toxicity of chemopreparation, frequency of adverse by-side effects and significant reducing the cost of chemotherapy. Invention can be used in carrying out the adjuvant chemoradiation therapy of brain malignant glial tumors.
EFFECT: improved method of chemoradiation therapy, enhanced effectiveness of method.
The invention relates to medicine, namely to Oncology, and can be used for adjuvant chemoradiation therapy of malignant glial tumors of the Central nervous system.
There is a method of treatment of malignant glial brain tumors by the combination of remote gemmoterapii with systemic chemotherapy drugs nitrosodiethylamine (Minesh Mehta, USA, "Combination therapy in malignant gliomas", Proceedings of the 12th conference on Oncology, Denmark, 21-25.09.2003, p.5), chosen as a prototype
The disadvantages of the method of treatment of malignant glial brain tumors are of low efficacy and high toxicity of chemotherapy.
The aim of the invention is to increase the efficiency and reduce the toxicity of treatment of malignant glial brain tumors.
This objective is achieved in that in the postoperative period the patient perform a lumbar puncture, kateteriziruyut subarachnoid space, take 5 ml of the liquor, incubated liquor with nimustine 5 mg in vitro at a temperature of 38°C for 30 minutes and injected through the catheter into the subarachnoid space, the procedure is carried out 2 times with an interval of 7 days. On day 2 start remote gamma-therapy is recommended (DHT) on the bed of the remote SDA is Oli daily for 20 days up to a total focal dose of 60 Gy. The invention "Method chemoradiation therapy of malignant glial brain tumors" is new, as it is not known from the level of medicine in the field of chemoradiation therapy of glial brain tumors.
The novelty of the invention lies in the fact that for the treatment of malignant glial brain tumors using the introduction of nimustine on autorequire through endolyumbalno catheter in combination with DHT.
The invention is industrially applicable as it can be used in health care, in medical institutions for the treatment of patients with tumors of the Central nervous system, cancer research institutes, breast care clinics and other clinical settings.
"The way chemoradiation therapy of malignant glial brain tumors" as follows:
in the postoperative period the patient perform a lumbar puncture needle (Tuohy, kateteriziruyut the subarachnoid space. Take the cerebrospinal fluid of a patient in an amount of 5 ml and incubated with the cancer - nimustine 5 mg in vitro at a temperature of 38°C for 30 minutes, and then endolyumbalno administered to the patient. The procedure is carried out twice with an interval of 7 days. On day 2 start remote gamma-therapy is recommended on the removed tumor bed daily for 20 days to total Chasovoy dose of 60 Gy.
"How chemoradiation therapy of malignant glial brain tumors"
Patient L-C H. C.,1989/R, case history No. 483/t, enrolled in the Department. INC RNII 20.01.2004 diagnosed with: medulloblastoma IV ventricle. Condition after suboccipital lymphadenopathy craniotomy with Subtotal removal of the tumor (23.12.2003,, RSMU, g/a No. 25924 - 31/03 - medulloblastoma). Admission: moderate cerebral m, expressed cerebellar ataxia; Karnofsky index was 50%, General health status who is 3 points. 20.01.04, - 12.02.2004 was held in the course of DHT SOD 60 Gy with intrathecal by autolymphochemotherapy (ALHT) nimustine 10 mg. Moved ALHT satisfactory - complications and side effects not. From 30.03. on 15.09.2004 was held for another 3 courses of intrathecal ALHT - 10 mg of nimustine. Portability ALHT satisfactory complications and side effects not. On CT brain 14.12.2004, in the zone of removal of the tumor of the left hemisphere of the cerebellum relapse no, liquor cavity, soamsawali with the fourth ventricle. Other parts of the brain - without lesions. The median structure without bias. After 4 courses of intrathecal chemotherapy the patient's condition is satisfactory, slight cerebral symptoms. Index on a scale Karnofsky 80%of the General status who is 1 point.
Techno-economic the th efficiency
"How chemoradiation therapy of malignant glial brain tumors" is that the use of nimustine in adjuvant endolyumbalno chemotherapy on autorequire in combination with remote gamma-therapy is recommended on the bed of the removed tumor allows to achieve stable remission after resection of malignant glial brain tumors, to reduce the toxicity of cytostatic agents, the incidence of side effects and thus increase the effectiveness of chemotherapy while significantly reducing its cost.
The way chemoradiation therapy of malignant glial brain tumors, including endolyumbalno introduction of hemipleat, characterized in that in the postoperative period the patient perform a lumbar puncture, kateteriziruyut subarachnoid space, take 5 ml of the liquor, incubated liquor with nimustine 5 mg in vitro at a temperature of 38°C for 30 min and injected through the catheter into the subarachnoid space, the procedure is carried out 2 times with an interval of 7 days, from the 2nd day of the beginning of the procedures performed remote gamma-therapy is recommended on the bed of the removed tumor to the total focal dose of 60 Gy.
FIELD: medicine, oncology, gynecology.
SUBSTANCE: method involves trepanopuncture of flank bone wing, aspiration of bone marrow suspension in the amount 150-200 ml followed by incubation of suspension with chemopreparations cisplatin and cyclophosphan at temperature 37°C for 40 min in doses above therapeutic ones. Doxorubicin is not incubated with bone marrow suspension and chemopreparations are administrated separately by intravenous route, by drops in indicated order in day when the bone marrow suspension has been taken, and this procedure is repeated with interval for 3-4 weeks but totally 4 times per one treatment course. Proposed method provides attaining the stable anti-tumor effect up to the complete tumor regression in this category of patients showing high tolerance to chemotherapy, and in practical absence of adverse toxic responses. Invention can be used in treatment of patients with relapses of ovary and uterus body cancer in case absence effectiveness of other methods of treatment or in case of their low effectiveness.
EFFECT: improved method of treatment.
FIELD: medicine, oncology.
SUBSTANCE: method involves administration of bleomycin and erythropoietin simultaneously in patients. Invention can be used for decreasing pulmonary cytotoxicity in patients treated with bleomycin. Invention provides improving functioning lung in patients of this category.
EFFECT: valuable medicinal properties of erythropoietin.
4 cl, 2 dwg, 2 ex
FIELD: medicine, oncology, pharmacology, pharmacy.
SUBSTANCE: invention relates to methods and medicinal formulations used in antitumor treatment and enhancing oral biological availability of taxanes. Method involves administration of taxane in combination with agent enhancing biological availability of taxane in oral administration in subject wherein concentrations of taxane attain levels of therapeutic activity in subject. Ketoconazol representing inhibitor of cytochrome P-450 is used as agent enhancing oral biological availability of taxane. Invention provides enhancing bioavailability of taxane in its oral administration in subject in subtherapeutic doses that results to decreasing toxicity of treatment.
EFFECT: improved and valuable medicinal properties of drug.
33 cl, 42 dwg, 10 tbl, 12 ex
FIELD: chemistry, medicine.
SUBSTANCE: invention relates to hemin-peptide of general formula I , wherein R1 is ArgTrpHisArgLeuLysGlu(OMe)OH; R2 is -OH; Y is Cl; Me is Fe, or pharmaceutically acceptable salts thereof having virulicidal and anti-viral activity, including activity against herpes virus and HIV, and capability for destroying of λ fag, herpes and HIV DNA. Hemin-peptide fragment also is disclosed.
EFFECT: new anti-viral agent.
2 cl, 5 tbl, 5 ex
FIELD: organic chemistry, biochemistry, medicine.
SUBSTANCE: invention relates to derivatives of 2-aminonicotine amide of the formula (I): , to methods of their synthesis and a pharmaceutical composition based on thereof inhibiting activity of receptor tyrosine kinase vessel endothelial growth factor (VEGF) and to corresponding method for inhibition of activity of VEGF-receptor tyrosine kinase. It is suggested that this activity will allow offering the curative effect in proliferative diseases associated with angiogenesis, in particular, in treatment of tumors, retinopathy or age degeneration of yellow (corneal) spot.
EFFECT: valuable medicinal properties of compounds and pharmaceutical composition.
9 cl, 42 ex
FIELD: medicine, ophthalmology, ophthalmooncology.
SUBSTANCE: one should intravenously inject a photosensitizer photosens at 0.1-1.0 mg/kg patient's body weight. In about 48-72 h since the moment of photosens injection it is important to detect the presence of preparation's therapeutic dosage in the tumor. For this purpose one should specify the coefficient of contrast degree between the tumor and healthy adjacent tissues. Planning of photodynamic therapy should be fulfilled individually by orienting to concrete values of the coefficient of contrast degree in a concrete patient. At the value of coefficient of contrast degree being ≥4, but under 10 it is necessary to irradiate with low single dosages (ranged 80-150 mW/sq. cm) by increasing the number of seances conducted (up to 10). At the value of the above-mentioned coefficient being ≥10.0 irradiation should be carried out once or during 2-3 seances at high single radiation dosages (ranged 150-800 mW/sq. cm). The innovation enables to optimize therapy in patients with intraocular tumors.
EFFECT: higher efficiency of therapy.
FIELD: organic chemistry, medicine, oncology.
SUBSTANCE: invention relates to using dicarboxylic acids of the general formula (2): R-CONH-OH (2) wherein R means -HO-HNCO, -HO-NHCOCH-(OH)CH(OH), -HOOC-CH2CH2, -HO-OCCH=CH as inhibitors of metastasis and agents enhancing chemotherapeutic activity of antitumor preparations. Also, invention relates to a method for enhancing effectiveness of cytostatics in carrying out cytostatic chemotherapy of tumors. Method is carried out by using cytostatics in combination with derivatives of dicarboxylic acids of the formula (2). Also, invention relates to a method for inhibition of metastasizing process. Method is carried out by effect of the known cytostatics and derivatives of dicarboxylic acid of the formula (2) on tumor. Proposed substances provide enhancing antitumor and anti-metastatic activity of known cytostatics based on using derivatives of dicarboxylic acids.
EFFECT: valuable medicinal properties of agents and preparations, enhanced effectiveness of metastasizing inhibition.
4 cl, 4 dwg, 7 ex
SUBSTANCE: method involves impregnating sterile gauze napkins with Tactivin solution, in the amount of 100 mcg per each napkin, and imposing it on mammary gland. Then, variable magnetic field treatment is applied. When applying the procedure one day and one hour prior to operation the napkins are arranged on both sides with respect to nodular formation, 3 cm far from it. When carrying out the procedure at the third day after operation, napkins are placed directly onto zone under operation.
EFFECT: reduced risk of complications in postoperative period.
SUBSTANCE: method involves concurrently giving Cyclopheron and Licopid under immunogram control at traditional doses and courses. Thus, if even one of parameters of immunogram, carried out in 2 months after treatment, does not reach normative limits, additional Licopid administration is applied under traditional preventive scheme.
EFFECT: enhanced effectiveness of immunocorrective and immononormalizing treatment; reduced risk of complications.
FIELD: medicine, pharmaceutical agents.
SUBSTANCE: disclosed is indolylacetic acid and sodium, potassium and lithium salts thereof having immunomodulatory (based on leukocyte levels in patient blood suffering from viral infection or after cytoctatic chemotherapy), anti-inflammation (based on normalizing of erythrocyte sedimentation rate and after ascyte treatment) and anti-tumor properties (in patient suffering from lymphoma and carcinoma). Said salts are produced by treatment of indolylacetic acid with solution of NaOH, or KOH, or LiOH, addition of heated distilled water in obtained solution, keeping at the same temperature to produce bright solution, followed by cooling and drying.
EFFECT: preparation with increased effectiveness, having no allergic action and other site effects.
3 cl, 5 ex
FIELD: medicine, radiation medicine.
SUBSTANCE: it has been suggested to apply lactoferrin as a curative preparation in case of acute radiation disease. Lactoferrin should be applied in the experiment at reproducing madullary form of acute radiation disease. Subcutaneous injection of lactoferrin in physiological solution at the dosage of 300 mcg/kg is accompanied with statistically significant increase of lymphocytes and neutrophils in peripheral blood that provides 100%-survival rate of irradiated animals in experimental group.
EFFECT: higher efficiency of therapy.
1 ex, 2 tbl
FIELD: medicine, oncology.
SUBSTANCE: the present innovation deals with adjuvant chemoradiation therapy of malignant cerebral meningiomas. In postsurgical period it is necessary to carry out lumbar puncture, catheterize subarachnoid space, sample 5 ml liquor, incubate liquor with cisplatin at the quantity of 0.1 mg in vitro at 38°C for 30 min to introduce it through a catheter into subarachnoid space. The procedure should be carried out twice at a 7-d-long interval, since the 2nd d of the beginning of this procedure it is necessary to conduct distance gamma-therapy at the bottom of removed tumor daily for 20 d up to total focal dosage being 60 Gy. The innovation enables to achieve stable remission, decrease toxicity of chemopreparation and frequency of side effects at considerable decrease of its cost price.
EFFECT: higher efficiency of therapy.
FIELD: medicine, oncogynecology.
SUBSTANCE: it is necessary to carry out expanded uterine extirpation and intrasurgical radiation therapy (ISRT). In women of reproductive age at squamous cell forms of uterine cervix cancer before the stage of expanded uterine extirpation one should fulfill ovarian transposition by fixing them in the upper departments of lateral canals of abdominal cavity to provide their functional safety and integrity of vascular peduncle. On finishing the stage of expanded uterine extirpation it is important to form the field of irradiation that includes vaginal stump and perivaginal fiber by restricting the organs of small pelvis and abdominal cavity against irradiation region. Irradiation should be carried out due to distance technique by providing the dosage of 15 Gy in the preset area. On finishing the ISRT seance it is necessary to conduct peritonization of small pelvis. The innovation enables to decrease the frequency of postsurgical complications that take place while ISRT procedure.
EFFECT: higher efficiency of therapy.
1 cl, 2 ex
FIELD: medicine, oncology, radiology.
SUBSTANCE: the suggested thermochemoradiation treatment should be fulfilled in three stages at intervals between each of them being 10-14 d: during the 1st stage it is necessary to carry out distance gamma-therapy daily at fractionating the dosage during 1-3 d per 4 Gy, then during 4-22 d per 2 Gy up to TFD being 50 isoGy, radiosensitization with 5-fluorouracil daily at the dosage of 125 mg intravenously at flow-type technique 30 min before the séance of radiation treatment and local thermotherapy with transrectal sensor once/2 d, every other day, just before gamma-therapy; during the 2nd stage it is necessary to conduct radiosensitization and local thermotherapy similarly, as it was during the first stage, as for irradiation it should be carried out as intracavitary gamma-therapy daily per 3 Gy up to TFD being 18-24 Gy; during the 3d stage one should fulfill radiosensitization with fluorouracil as during the first and second stages and carry out distance gamma-therapy daily per 2 Gy so that TFD from all three stages should achieve 74 isoGy.
EFFECT: higher efficiency of therapy.
FIELD: medicine, oncology.
SUBSTANCE: the present innovation deals with complex therapy of mammary gland cancer at T1-2NO-1MO. The method includes chemo- and radiation therapy and operation procedure. Moreover, in post-surgical period, before the onset of radiation therapy course it is necessary to sample 200 ml patient's blood and due to centrifuging technique isolate autoplasma. One should place 20 ml autoplasma and chemopreparations into the first vial, into the second vial - remained blood cells and autoplasma. Vials should be separately incubated for 40 min at 37° C, then during the first day of radiation therapy before the onset of the seance one should introduce the half of autoplasma volume incubated with chemopreparations from the first vial into the ducts of operated mammary gland, as for the remained part of autoplasma incubated with chemopreparations, from the first vial it should be introduced into the site of surgical withdrawal of drainage tube. Blood incubated with chemopreparations from the second vial should be reinfused intravenously by drops. The innovation is of low toxicity and enables to carry out complex organ-saving therapy in short terms, decrease the frequency of local relapses and remote metastases, the number of radiation reactions and complications.
EFFECT: higher efficiency.
FIELD: methods and devices for treatment of oncology patients using sources of ionizing radiation, namely, technology of pre-irradiation preparation and irradiation during intracavitary and interstitial radiotherapy.
SUBSTANCE: method for pre-irradiation preparation and irradiation includes positioning the patient on treatment-diagnostics table, inserting into cavity to be irradiated of hollow applicators with imitators of ionizing radiation sources, controlling position thereof relatively to target being irradiated with usage of x-ray television device, building of dosimetric plane and irradiation, while applicators inserted into cavity being irradiated are connected to treatment-diagnostics table, x-ray radiography is performed with output of image onto monitor of viewing station of x-ray television device, image via the interface is transported into planning system, dosimetric plane of irradiation is computed, which is then exported into system for controlling device and irradiation procedure is performed. Treatment-diagnostics table has frame, two supporting posts with overhung table top mounted on them, consisting of a pelvic-dorsal and two extending leg sections, connected to pelvic-dorsal section by means of twin joints. For connection of applicator table is provided with mounting pillar.
EFFECT: possible irradiation directly near apparatus without moving the patient during x-ray control of position of applicators and, therefore, increased quality of radiotherapy and therapeutic efficiency, decreased duration of pre-irradiation preparation.
2 cl, 3 dwg
FIELD: medicine, in particular, radiotherapy.
SUBSTANCE: during irradiation of oncology patients on cobalt distance apparatuses dose field is formed by injecting topographic-anatomic information of patient into dose planning system and generating with its consideration of main dose field on basis of results of calculations of main dose field, dose deficiency area is located within limits of target and iso-centers of additional dose fields are positioned therein, while width of radiation beams, generating additional dose fields, is less than width of beam of main dose fields 1,5-2,5 times, while value of dose of main field is 0,7-0,85 of resulting dose within limits of target.
EFFECT: possible generation of dose field with minimal possible dose change on target while simultaneously decreasing radiation loads on normal tissues and skin.
2 dwg, 1 ex
FIELD: medicine, in particular, oncology.
SUBSTANCE: in accordance to method, thermo-radio-therapy of malignant tumors is performed in form of split course in mode of enlarged dynamic fractioning of dose in 6 fractions of 4 Gy and 8 fractions of 2 Gy in first course, and 6 fractions of 4 Gy and 3 fractions of 2 Gy in second course in conjunction with hyper-thermal effect in the same day when radio-therapy is performed.
EFFECT: increased apparent counter-tumor local effect.
FIELD: medicine, namely, medicinal use of radiation, possible use for determining dose really received by pathologic focus having absorbed open radioactive nuclide.
SUBSTANCE: method for verification of dose during medicinal usage of open radioactive nuclides includes measuring intensiveness of radiation, with consideration of changes in radiation source activity in time, during that, by means of tissue-equivalent phantom, original intensiveness of radiation of open radionuclide is measured immediately prior to injecting it into organism of patient as well as average intensiveness of radiation from focuses having absorbed radionuclide, and after that individual relative dose of open radionuclide injected into pathologic focuses is computed using formula
where Dn/o - value of relative dose in %, Io - original intensiveness of radiation at the moment of injection of radionuclide, In - average intensiveness of radiation from focuses at day or hour of measurement of n, B0 and Bn - background values of radiation intensiveness at the moment of injection of radionuclide and at the day of measurement, respectively, k - coefficient of daily or hourly decomposition of radionuclide, n - number of days or hours having passed since the moment of injection of radionuclide.
EFFECT: invention allows verification of relative dose in most precise and individual manner.
FIELD: medical facilities.
SUBSTANCE: device can be used as a tool for malignant tumors surgery. Device for radionuclide surgery has gamma radiation detector, collimator and handle. Wire of detector is connected with measuring unit. Gamma radiation detector is fixed in metal tip with sharpened side edge, which passes in plane being perpendicular to optical axis of gamma radiation detector. Detector is made in form of semiconductor crystal; two collimators adjoin opposite surfaces of crystal. Collimators have cells which pass in parallel to optical axis of gamma detector. Measuring unit has electronic circuit with sonic signal source.
EFFECT: ability of reaching area of lesion for removing it.
4 cl, 2 dwg
FIELD: medicine, gastroenterology, pancreatology, reanimation.
SUBSTANCE: method involves carrying out epidural anesthesia at the level ThIX - ThXI with 0.2% ropivacaine solution that is administrated at the rate 4-5 ml/h for 72 h. Epidural infusion is combined with intravenous administration of the preparation "Essentiale" in the dose 10 ml of solution in 200 ml of 0.9% NaCl, 2 times per 24 h. Invention provides adequate anti-stress protection and analgesic effect and with retention of motor activity of patient. Invention can be used in treatment of acute destructive pancreatitis in early period.
EFFECT: improved and enhanced effectiveness of treatment.